{"prompt": "['6 STUDY INTERVENTION', '6.1', 'Study Product Description', 'ITI-007 will be supplied as 60-mg over-encapsulated tablets (capsules) (Table ). The', 'following drug supplies will be used in the study:', 'Table 6-1', 'Table for Dosing Schedule', 'Study Treatment', 'Dosing Schedule', '1 over-encapsulated tablet of 60-mg ITI-007', '60-mg ITI-007', 'Daily Dose: 60-mg ITI-007', '1 over-encapsulated tablet of placebo', 'Placebo', 'Daily Dose: 0-mg ITI-007', 'ITI-007 60 mg refers to the tosylate salt (ITI-007 tosylate or lumateperone tosylate) and', 'is equivalent to 42 mg of the active base (lumateperone).', 'Each ITI-007 dosing container will be labeled according to local laws and regulations.', 'The composition of the over-encapsulated tablets is listed in Table 6-2.', 'Intra-Cellular Therapies, Inc. Confidential', '22 ITI-007-404 Protocol Amendment V 1.3 November 5, 2018']['Intra-Cellular Therapies, Inc. Confidential', '23 ITI-007-404 Protocol Amendment V 1.3 November 5, 2018']['6.1.1 Acquisition', 'Adequate supplies of ITI-007 and matched placebo will be provided to each study site.', '6.1.2', 'Formulation, Packaging, and Labeling', 'ITI-007 and matching placebo will be prepared according to current Good', 'Manufacturing Practice standards in carded blister strips and shipped under ambient', 'conditions. Each treatment card will contain a sufficient quantity of capsules for 1', 'patient for two weeks (14 doses, plus 2 extras), to be dispensed every other visit of the', '6-week treatment period. Each ITI-007 dosing container will be labeled according to', 'local laws and regulations.', 'The dose card for each study treatment will contain two 1x8 strips of over-encapsulated', 'tablets (final product in capsule form) as described in Table 6-.', 'Table 6-3', 'Bi-Weekly Treatment Cards', 'Treatment', 'Card Contents', 'Placebo', 'Two 1x8 strips of placebo over-', 'encapsulated tablets (8 over-', 'encapsulated tablets/strip)', '60-mg ITI-007', 'Two 1x8 strips of 60-mg ITI-007 over-', 'encapsulated tablets (8 over-', 'encapsulated tablets/strip)', 'Note: Each card will hold 16 over-encapsulated tablets in 2 strips of 8.', '6.1.3', 'Product Storage and Stability', 'Study treatment must be stored in a secure area (e.g., a locked cabinet) while in', 'storage at the study site, protected from moisture, and kept at a room temperature', 'between 15\u00b0C and 30\u00b0C (59\u00b0F-86\u00b0F). Patients will be instructed to store the bi-weekly', 'treatment card at room temperature at home, out of the reach of children. Patients will', 'be instructed to take 1 capsule per dose. Patients will be instructed to bring the bi-', 'weekly treatment card to the study site at the next visit to assess compliance.', 'Intra-Cellular Therapies, Inc. Confidential', '24 ITI-007-404 Protocol Amendment V 1.3 November 5, 2018']\n\n###\n\n", "completion": "END"}